Anja Gesierich

7.2k total citations
64 papers, 1.3k citations indexed

About

Anja Gesierich is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Anja Gesierich has authored 64 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 28 papers in Molecular Biology and 11 papers in Epidemiology. Recurrent topics in Anja Gesierich's work include Melanoma and MAPK Pathways (18 papers), Cutaneous Melanoma Detection and Management (14 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Anja Gesierich is often cited by papers focused on Melanoma and MAPK Pathways (18 papers), Cutaneous Melanoma Detection and Management (14 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Anja Gesierich collaborates with scholars based in Germany, United States and France. Anja Gesierich's co-authors include Matthias Goebeler, Bastian Schilling, Claus Garbe, Ralf Gutzmer, Dirk Schadendorf, Götz Gelbrich, Lisa Zimmer, Selma Ugurel, Dédée F. Murrell and Jeannie Hou and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Anja Gesierich

55 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anja Gesierich Germany 17 785 602 371 267 239 64 1.3k
Catalin Mihalcioiu Canada 14 422 0.5× 391 0.6× 179 0.5× 131 0.5× 155 0.6× 38 1000
Joanna Mangana Switzerland 20 710 0.9× 441 0.7× 153 0.4× 110 0.4× 292 1.2× 82 1.2k
J. J. Bonerandi France 14 783 1.0× 464 0.8× 292 0.8× 264 1.0× 171 0.7× 25 1.4k
Friederike Egberts Germany 23 707 0.9× 613 1.0× 164 0.4× 177 0.7× 245 1.0× 57 1.3k
Jean-Jacques Grob France 7 1.4k 1.7× 547 0.9× 176 0.5× 102 0.4× 541 2.3× 9 1.6k
Kenjiro Namikawa Japan 18 920 1.2× 463 0.8× 233 0.6× 211 0.8× 279 1.2× 104 1.2k
Imke Satzger Germany 26 1.2k 1.5× 595 1.0× 362 1.0× 332 1.2× 334 1.4× 55 1.8k
L. Peuvrel France 19 493 0.6× 280 0.5× 186 0.5× 244 0.9× 152 0.6× 63 853
Florentia Dimitriou Switzerland 16 665 0.8× 250 0.4× 133 0.4× 161 0.6× 230 1.0× 50 936
Marjorie H. Colman Australia 15 1.2k 1.5× 592 1.0× 248 0.7× 125 0.5× 152 0.6× 18 1.4k

Countries citing papers authored by Anja Gesierich

Since Specialization
Citations

This map shows the geographic impact of Anja Gesierich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anja Gesierich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anja Gesierich more than expected).

Fields of papers citing papers by Anja Gesierich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anja Gesierich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anja Gesierich. The network helps show where Anja Gesierich may publish in the future.

Co-authorship network of co-authors of Anja Gesierich

This figure shows the co-authorship network connecting the top 25 collaborators of Anja Gesierich. A scholar is included among the top collaborators of Anja Gesierich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anja Gesierich. Anja Gesierich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arnold, L, Friedegund Meier, Katharina Meier, et al.. (2025). Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis. Journal for ImmunoTherapy of Cancer. 13(9). e013038–e013038.
2.
Lodde, Georg, Ulrike Leiter, Anja Gesierich, et al.. (2025). Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients. European Journal of Cancer. 221. 115406–115406. 1 indexed citations
3.
4.
Livingstone, Elisabeth, Kai‐Martin Thoms, Markus V. Heppt, et al.. (2025). Real‐world management of patients with complete response under immune‐checkpoint inhibition for advanced melanoma. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 23(3). 321–327.
5.
6.
Gesierich, Anja, E. Demeter, Bastian Schilling, & Barbara Deschler-Baier. (2025). More than age: Impact of comorbidity and polypharmacy on immune-related adverse events, treatment discontinuation, and toxicity management in older patients receiving immune checkpoint inhibitors. Journal of Geriatric Oncology. 17(1). 102813–102813.
7.
Ivanyi, Philipp, Bernd Alt‐Epping, Lars Bullinger, et al.. (2025). Quality of Life of Cancer Patients in Routine Clinical Care Using the Example of Checkpoint Inhibition Therapy: A Delphi Consensus. Oncology Research and Treatment. 48(9). 498–505.
8.
Sinnberg, Tobias, Ulrich Dischinger, Markus V. Heppt, et al.. (2024). Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils. Cancers. 16(9). 1767–1767. 1 indexed citations
9.
Sekulović, Lidija Kandolf, Friedegund Meier, Thomas Eigentler, et al.. (2024). LBA45 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial. Annals of Oncology. 35. S1235–S1236. 1 indexed citations
10.
Forschner, Andrea, Ulrike Leiter, Friedegund Meier, et al.. (2024). Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors. European Journal of Cancer. 203. 114028–114028. 24 indexed citations
11.
12.
Scherzad, Agmal, Till Meyer, Thomas Gehrke, et al.. (2023). Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real-world data of a retrospective, single-center study. European Archives of Oto-Rhino-Laryngology. 280(9). 4215–4223. 6 indexed citations
13.
Dischinger, Ulrich, Markus V. Heppt, Kilian Wistuba‐Hamprecht, et al.. (2022). Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma. Cancers. 14(9). 2294–2294. 9 indexed citations
14.
Glutsch, Valerie, Hermann Kneitz, Matthias Goebeler, Anja Gesierich, & Bastian Schilling. (2019). Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?. Annals of Oncology. 30(10). 1667–1668. 12 indexed citations
15.
Gesierich, Anja, Thomas Eigentler, Cindy Franklin, et al.. (2019). Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. European Journal of Cancer. 116. 207–215. 28 indexed citations
16.
Glutsch, Valerie, et al.. (2019). Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy. Journal for ImmunoTherapy of Cancer. 7(1). 181–181. 15 indexed citations
17.
Braunmühl, Tanja von, Cyrus Sayehli, Anja Gesierich, et al.. (2017). Sézary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis. Acta Dermato Venereologica. 97(8). 973–975. 1 indexed citations
18.
Baur, Johannes, Anja Gesierich, Gerhard Weyandt, et al.. (2017). Morbidity and oncologic outcome after saphenous vein-sparing inguinal lymphadenectomy in melanoma patients. World Journal of Surgical Oncology. 15(1). 99–99. 6 indexed citations
19.
Bluemel, Christina, Achim Wöckel, Anja Gesierich, et al.. (2016). Fusion of freehand SPECT and ultrasound: First experience in preoperative localization of sentinel lymph nodes. European Journal of Nuclear Medicine and Molecular Imaging. 43(13). 2304–2312. 25 indexed citations
20.
Weyandt, Gerhard, Anja Gesierich, & Henning Hamm. (2009). Unguis incarnatus: fadenfixierte Nagelschienung mit gespaltener Redondrainage. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 7(2). 169–171. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catalin Mihalcioiu Breakdown of academic impact, for papers by Joanna Mangana Breakdown of academic impact, for papers by J. J. Bonerandi Breakdown of academic impact, for papers by Friederike Egberts Breakdown of academic impact, for papers by Jean-Jacques Grob Breakdown of academic impact, for papers by Kenjiro Namikawa Breakdown of academic impact, for papers by Imke Satzger Breakdown of academic impact, for papers by L. Peuvrel Breakdown of academic impact, for papers by Florentia Dimitriou Breakdown of academic impact, for papers by Marjorie H. Colman
Rankless by CCL
2026